HER2-targeted multimodal imaging of anaplastic thyroid cancer.
暂无分享,去创建一个
Zachary T. Rosenkrans | W. Cai | J. Engle | T. Barnhart | Dawei Jiang | Weijun Wei | Quan-Yong Luo | Z. Rosenkrans
[1] B. Prabhakar,et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective , 2018, Molecular Cancer.
[2] Dalong Ni,et al. Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. , 2018, Journal of the American Chemical Society.
[3] G. Rätsch,et al. EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. , 2018, Cancer discovery.
[4] M. Piccart,et al. Progress in adjuvant systemic therapy for breast cancer , 2018, Nature Reviews Clinical Oncology.
[5] W. Oyen,et al. Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. , 2018, European urology.
[6] W. Cai,et al. Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. , 2018, American journal of nuclear medicine and molecular imaging.
[7] Emily B. Ehlerding,et al. PET Imaging of Receptor Tyrosine Kinases in Cancer , 2018, Molecular Cancer Therapeutics.
[8] M. Bartholomä. Radioimmunotherapy of solid tumors: Approaches on the verge of clinical application. , 2018, Journal of labelled compounds & radiopharmaceuticals.
[9] M. Piccart,et al. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. , 2018, Cancer treatment reviews.
[10] N. S. van den Berg,et al. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers , 2018, Theranostics.
[11] Travis M. Shaffer,et al. Nanoparticles as multimodal photon transducers of ionizing radiation , 2018, Nature Nanotechnology.
[12] Johan F. Langenhuijsen,et al. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study , 2018, Theranostics.
[13] S. Achilefu,et al. Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer , 2018, Nature Communications.
[14] B. Taylor,et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers , 2018, Nature.
[15] Gary A Ulaner,et al. First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer , 2017, The Journal of Nuclear Medicine.
[16] B. Schneider,et al. Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer , 2017, The oncologist.
[17] J. Schellens,et al. Fixed Dosing of Monoclonal Antibodies in Oncology , 2017, The oncologist.
[18] A. Ribechini,et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies , 2017, Nature Reviews Endocrinology.
[19] V. Tolmachev,et al. Pretargeted Imaging and Therapy , 2017, The Journal of Nuclear Medicine.
[20] Sarah E. Pinder,et al. Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using 18F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study , 2017, The Journal of Nuclear Medicine.
[21] Emily B. Ehlerding,et al. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[22] W. Cai,et al. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[23] Jan Grimm,et al. Utilizing the power of Cerenkov light with nanotechnology. , 2017, Nature nanotechnology.
[24] F. Trimarchi,et al. HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin , 2016, International journal of molecular sciences.
[25] Jan Grimm,et al. Optical Imaging of Ionizing Radiation from Clinical Sources , 2016, The Journal of Nuclear Medicine.
[26] Serge K. Lyashchenko,et al. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT , 2016, The Journal of Nuclear Medicine.
[27] J. Fagin,et al. Biologic and Clinical Perspectives on Thyroid Cancer. , 2016, The New England journal of medicine.
[28] Emily B. Ehlerding,et al. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody , 2016, Theranostics.
[29] W. Oyen,et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] S. Beriwal,et al. Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival , 2016, Head & neck.
[31] S. Strand,et al. Radioimmunotherapy for Prostate Cancer--Current Status and Future Possibilities. , 2016, Seminars in nuclear medicine.
[32] King Li,et al. Preliminary Therapy Evaluation of 225Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization , 2016, Theranostics.
[33] C. Sander,et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. , 2016, The Journal of clinical investigation.
[34] A. Świerniak,et al. Gene signature of the post-Chernobyl papillary thyroid cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[35] Vasilis Ntziachristos,et al. Advancing Surgical Vision with Fluorescence Imaging. , 2016, Annual review of medicine.
[36] S. Larson,et al. Radioimmunotherapy of human tumours , 2015, Nature Reviews. Cancer.
[37] T. Reiner,et al. Cerenkov Luminescence Imaging for Radiation Dose Calculation of a 90Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist , 2015, The Journal of Nuclear Medicine.
[38] E. Kebebew,et al. Management of anaplastic thyroid cancer. , 2015, Gland surgery.
[39] Joshua S Richman,et al. Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer , 2015, Clinical Cancer Research.
[40] S. Davis,et al. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer , 2015, Oncotarget.
[41] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[42] Samuel Achilefu,et al. Breaking the Depth Dependency of Phototherapy with Cerenkov Radiation and Low Radiance Responsive Nanophotosensitizers , 2015, Nature nanotechnology.
[43] Muhan Liu,et al. Feasibility study of novel endoscopic Cerenkov luminescence imaging system in detecting and quantifying gastrointestinal disease: first human results , 2015, European Radiology.
[44] S. Mane,et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. , 2015, Human molecular genetics.
[45] P. Meltzer,et al. Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer. , 2014, American journal of cancer research.
[46] W. Oyen,et al. Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry , 2014, Front. Med..
[47] Steven J. M. Jones,et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.
[48] J. Bading,et al. Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET , 2014, The Journal of Nuclear Medicine.
[49] O. Yamada,et al. Amplification of the human epidermal growth factor receptor 2 gene in differentiated thyroid cancer correlates with telomere shortening. , 2013, International journal of oncology.
[50] M. Xing,et al. Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.
[51] C. Sotiriou,et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] Carlo Cavedon,et al. First human Cerenkography , 2013, Journal of biomedical optics.
[53] M. Bui,et al. HER2-positive male breast cancer with thyroid cancer: an institutional report and review of literature. , 2012, Annals of clinical and laboratory science.
[54] Zhen Cheng,et al. Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging , 2011, The Journal of Nuclear Medicine.
[55] Kendall W. Cradic,et al. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. , 2010, The Journal of clinical endocrinology and metabolism.
[56] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.
[57] P. Jurek,et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.
[58] Tetsu Kobayashi,et al. Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.
[59] C. Nucera,et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. , 2009, Thyroid : official journal of the American Thyroid Association.
[60] John M S Bartlett,et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] J. Copland,et al. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. , 2008, Endocrine-related cancer.
[62] Raimund J. Ober,et al. Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn1 , 2004, The Journal of Immunology.
[63] Raimund J Ober,et al. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. , 2003, International immunology.
[64] T. Seyama,et al. Establishment of 2 human thyroid-carcinoma cell-lines (8305c, 8505c) bearing p53 gene-mutations. , 1994, International journal of oncology.
[65] C. Damsky,et al. Invasion by cultured human follicular thyroid cancer correlates with increasedβ1 integrins and production of proteases , 1992, World Journal of Surgery.
[66] H. Sato,et al. Establishment and biological characterization of an in vitro human cytomegalovirus latency model. , 1987, Virology.
[67] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[68] P. Wen,et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] Weibo Cai,et al. Multimodality imaging of the HER-kinase axis in cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[70] A. Frilling,et al. Growth regulation of normal thyroids and thyroid tumors in man. , 1990, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.